Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70), a Kelowna-based consumer product innovation company focused on oral pouch and functional stimulant technologies, announced on September 30, 2026 a series of board and executive leadership changes alongside a completed shares-for-debt settlement. The company appointed Kareem Baalbaki as interim CEO, interim CFO, and director, and Jeremy Wright as a new director, while former CEO Chris Jackson and former CFO Chris Cherry both resigned. Investors may be watching how the leadership transition shapes Doseology's operational and financial direction.

Key Points

  • Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70) is a consumer product innovation company specialising in oral pouch and functional stimulant products.
  • Kareem Baalbaki appointed interim CEO, interim CFO, and director; Jeremy Wright appointed as director, effective September 30, 2026.
  • 75,268 common shares issued at $0.18 per share to settle $13,548.39 in accrued consulting compensation.
  • Investors may be watching how incoming leadership stabilises operations and advances the company's oral pouch product strategy.

Baalbaki Brings CPG and Supply Chain Depth to Doseology's Interim Executive Roles

Kareem Baalbaki, the newly appointed interim CEO and interim CFO, is described in the release as an operations and supply chain executive with more than ten years of experience scaling high-growth businesses. He previously served as Chief Supply Chain Officer at Revive Superfoods, where he helped grow annual revenue from approximately $10 million to $150 million. Based in Toronto, Ontario, he holds a Master of Science in International Business from the University of Lincoln, United Kingdom, and brings hands-on consumer packaged goods experience in operations, governance, and organisational design.

Jeremy Wright Adds Public-Market Finance Experience to Doseology's Board

Jeremy Wright, CPA, CMA, joins Doseology's board as a director while serving as CFO of Avant Brands Inc. (TSX: AVNT). The release notes he was founding CFO of GTEC Holdings, helping raise more than $45 million prior to its TSX uplisting. He also served as CFO of Alpha Cognition Inc., assisting in raising more than $20 million during its early public-company years. A former Senior Manager at Deloitte LLP (Canada), Wright brings Big Four training and capital-markets execution experience across the TSX and Nasdaq exchanges.

Doseology Completes Shares-for-Debt Settlement at $0.18 Per Share

Concurrent with the leadership announcement, Doseology disclosed the completion of a shares-for-debt settlement first referenced in a September 23, 2026 news release. The company issued an aggregate of 75,268 common shares at a deemed price of $0.18 per share to settle $13,548.39 in accrued share-based consulting compensation owed to a former consultant. The release states that the settlement shares are subject to applicable resale restrictions under Canadian securities laws. The immediate share price impact was not clear from available public information.